Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2025)

Cytosorbents (CTSO) has disclosed Asset Writedowns and Impairment for 13 consecutive years, with $244000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment fell 14.08% year-over-year to $244000.0, compared with a TTM value of $273735.0 through Sep 2025, down 44.48%, and an annual FY2024 reading of $333735.0, down 49.1% over the prior year.
  • Asset Writedowns and Impairment was $244000.0 for Q3 2025 at Cytosorbents, up from $7110.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $305505.0 in Q1 2022 and bottomed at -$281151.0 in Q2 2022.
  • Average Asset Writedowns and Impairment over 5 years is $64923.9, with a median of $19720.0 recorded in 2021.
  • Peak annual rise in Asset Writedowns and Impairment hit 1449.21% in 2022, while the deepest fall reached 1325.72% in 2022.
  • Year by year, Asset Writedowns and Impairment stood at -$6649.0 in 2021, then plummeted by 181.59% to -$18723.0 in 2022, then skyrocketed by 1061.73% to $180064.0 in 2023, then tumbled by 88.48% to $20735.0 in 2024, then skyrocketed by 1076.75% to $244000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for CTSO at $244000.0 in Q3 2025, $7110.0 in Q2 2025, and $1890.0 in Q1 2025.